Literature DB >> 24363131

C9orf72 expansions are the most common genetic cause of Huntington disease phenocopies.

Davina J Hensman Moss1, Mark Poulter, Jon Beck, Jason Hehir, James M Polke, Tracy Campbell, Garry Adamson, Ese Mudanohwo, Peter McColgan, Andrea Haworth, Edward J Wild, Mary G Sweeney, Henry Houlden, Simon Mead, Sarah J Tabrizi.   

Abstract

OBJECTIVE: In many cases where Huntington disease (HD) is suspected, the genetic test for HD is negative: these are known as HD phenocopies. A repeat expansion in the C9orf72 gene has recently been identified as a major cause of familial and sporadic frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Our objective was to determine whether this mutation causes HD phenocopies.
METHODS: A cohort of 514 HD phenocopy patients were analyzed for the C9orf72 expansion using repeat primed PCR. In cases where the expansion was found, Southern hybridization was performed to determine expansion size. Clinical case notes were reviewed to determine the phenotype of expansion-positive cases.
RESULTS: Ten subjects (1.95%) had the expansion, making it the most common identified genetic cause of HD phenocopy presentations. The size of expansion was not significantly different from that associated with other clinical presentations of C9orf72 expanded cases. The C9orf72 expansion-positive subjects were characterized by the presence of movement disorders, including dystonia, chorea, myoclonus, tremor, and rigidity. Furthermore, the age at onset in this cohort was lower than previously reported for subjects with the C9orf72 expansion and included one case with pediatric onset. DISCUSSION: This study extends the known phenotype of the C9orf72 expansion in both age at onset and movement disorder symptoms. We propose a revised clinico-genetic algorithm for the investigation of HD phenocopy patients based on these data.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24363131      PMCID: PMC3929197          DOI: 10.1212/WNL.0000000000000061

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  35 in total

1.  Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS.

Authors:  Mariely DeJesus-Hernandez; Ian R Mackenzie; Bradley F Boeve; Adam L Boxer; Matt Baker; Nicola J Rutherford; Alexandra M Nicholson; NiCole A Finch; Heather Flynn; Jennifer Adamson; Naomi Kouri; Aleksandra Wojtas; Pheth Sengdy; Ging-Yuek R Hsiung; Anna Karydas; William W Seeley; Keith A Josephs; Giovanni Coppola; Daniel H Geschwind; Zbigniew K Wszolek; Howard Feldman; David S Knopman; Ronald C Petersen; Bruce L Miller; Dennis W Dickson; Kevin B Boylan; Neill R Graff-Radford; Rosa Rademakers
Journal:  Neuron       Date:  2011-09-21       Impact factor: 17.173

2.  Huntington's disease out of the closet?

Authors:  Michael Rawlins
Journal:  Lancet       Date:  2010-06-30       Impact factor: 79.321

3.  Comparison of family histories in FTLD subtypes and related tauopathies.

Authors:  J S Goldman; J M Farmer; E M Wood; J K Johnson; A Boxer; J Neuhaus; C Lomen-Hoerth; K C Wilhelmsen; V M-Y Lee; M Grossman; B L Miller
Journal:  Neurology       Date:  2005-12-13       Impact factor: 9.910

4.  Huntington's disease CAG trinucleotide repeats in pathologically confirmed post-mortem brains.

Authors:  F Persichetti; J Srinidhi; L Kanaley; P Ge; R H Myers; K D'Arrigo; G T Barnes; M E MacDonald; J P Vonsattel; J F Gusella
Journal:  Neurobiol Dis       Date:  1994-12       Impact factor: 5.996

5.  Huntington disease without CAG expansion: phenocopies or errors in assignment?

Authors:  S E Andrew; Y P Goldberg; B Kremer; F Squitieri; J Theilmann; J Zeisler; H Telenius; S Adam; E Almquist; M Anvret
Journal:  Am J Hum Genet       Date:  1994-05       Impact factor: 11.025

Review 6.  The Huntington's disease-like syndromes: what to consider in patients with a negative Huntington's disease gene test.

Authors:  Susanne A Schneider; Ruth H Walker; Kailash P Bhatia
Journal:  Nat Clin Pract Neurol       Date:  2007-09

Review 7.  Recent advances in the genetics of the ALS-FTLD complex.

Authors:  Huw R Morris; Adrian J Waite; Nigel M Williams; James W Neal; Derek J Blake
Journal:  Curr Neurol Neurosci Rep       Date:  2012-06       Impact factor: 5.081

8.  RANTing about C9orf72.

Authors:  Tammaryn Lashley; John Hardy; Adrian M Isaacs
Journal:  Neuron       Date:  2013-02-20       Impact factor: 17.173

9.  A distinct clinical, neuropsychological and radiological phenotype is associated with progranulin gene mutations in a large UK series.

Authors:  Jonathan Beck; Jonathan D Rohrer; Tracy Campbell; Adrian Isaacs; Karen E Morrison; Emily F Goodall; Elizabeth K Warrington; John Stevens; Tamas Revesz; Janice Holton; Safa Al-Sarraj; Andrew King; Rachael Scahill; Jason D Warren; Nick C Fox; Martin N Rossor; John Collinge; Simon Mead
Journal:  Brain       Date:  2008-01-29       Impact factor: 13.501

10.  Behavioral variant frontotemporal lobar degeneration with amyotrophic lateral sclerosis with a chromosome 9p21 hexanucleotide repeat.

Authors:  Robert P Friedland; Jignesh J Shah; Lindsay A Farrer; Badri Vardarajan; Jovan D Rebolledo-Mendez; Kin Mok; John Hardy
Journal:  Front Neurol       Date:  2012-10-04       Impact factor: 4.003

View more
  77 in total

Review 1.  Familial Amyotrophic Lateral Sclerosis.

Authors:  Kevin Boylan
Journal:  Neurol Clin       Date:  2015-09-08       Impact factor: 3.806

2.  C9ORF72 intermediate repeat expansion in patients affected by atypical parkinsonian syndromes or Parkinson's disease complicated by psychosis or dementia in a Sardinian population.

Authors:  Antonino Cannas; Paolo Solla; Giuseppe Borghero; Gian Luca Floris; Adriano Chio; Marcello Mario Mascia; Nicola Modugno; Antonella Muroni; Gianni Orofino; Francesca Di Stefano; Andrea Calvo; Cristina Moglia; Gabriella Restagno; Mario Meloni; Rita Farris; Daniela Ciaccio; Roberta Puddu; Melisa Iris Vacca; Rosanna Melis; Maria Rita Murru; Stefania Tranquilli; Daniela Corongiu; Marcella Rolesu; Stefania Cuccu; Maria Giovanna Marrosu; Francesco Marrosu
Journal:  J Neurol       Date:  2015-08-15       Impact factor: 4.849

Review 3.  The phenotypic variability of amyotrophic lateral sclerosis.

Authors:  Bart Swinnen; Wim Robberecht
Journal:  Nat Rev Neurol       Date:  2014-10-14       Impact factor: 42.937

Review 4.  Emerging role of RNA•DNA hybrids in C9orf72-linked neurodegeneration.

Authors:  Jiou Wang; Aaron R Haeusler; Eric A J Simko
Journal:  Cell Cycle       Date:  2015       Impact factor: 4.534

5.  Huntington's disease: lessons from prion disorders.

Authors:  Melanie Alpaugh; Francesca Cicchetti
Journal:  J Neurol       Date:  2021-02-24       Impact factor: 4.849

Review 6.  Genetics of Movement Disorders and the Practicing Clinician; Who and What to Test for?

Authors:  Alessio Di Fonzo; Edoardo Monfrini; Roberto Erro
Journal:  Curr Neurol Neurosci Rep       Date:  2018-05-23       Impact factor: 5.081

7.  To Dement or Not to Dement, That Is the Question.

Authors:  Bryan J Traynor; Yevgeniya A Abramzon
Journal:  JAMA Neurol       Date:  2016-04       Impact factor: 18.302

8.  Multiple variants in families with amyotrophic lateral sclerosis and frontotemporal dementia related to C9orf72 repeat expansion: further observations on their oligogenic nature.

Authors:  Maria Pia Giannoccaro; Anna Bartoletti-Stella; Silvia Piras; Annalisa Pession; Patrizia De Massis; Federico Oppi; Michelangelo Stanzani-Maserati; Elena Pasini; Simone Baiardi; Patrizia Avoni; Piero Parchi; Rocco Liguori; Sabina Capellari
Journal:  J Neurol       Date:  2017-06-15       Impact factor: 4.849

Review 9.  Antisense oligonucleotide therapy for the treatment of C9ORF72 ALS/FTD diseases.

Authors:  Giulietta Riboldi; Chiara Zanetta; Michela Ranieri; Monica Nizzardo; Chiara Simone; Francesca Magri; Nereo Bresolin; Giacomo P Comi; Stefania Corti
Journal:  Mol Neurobiol       Date:  2014-05-09       Impact factor: 5.590

Review 10.  R Loops and Links to Human Disease.

Authors:  Patricia Richard; James L Manley
Journal:  J Mol Biol       Date:  2016-09-04       Impact factor: 5.469

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.